While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

Scholar Rock's latest trial returned very positive results. Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, ...

Scholar Rock (NASDAQ: SRRK) has reported positive results from the phase 2 Embraze trial, demonstrating statistically ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

We recently published a list of These 10 Stocks Boast Double-Digit Gains Amid Boring Market. Scholar Rock Holding Corporation ...

Scholar Rock (Nasdaq: SRRK) has unveiled encouraging Phase II data for its experimental therapy apitegromab, showing the drug ...

Shares of Scholar Rock (SRRK) soared 16% on Wednesday after the company announced that its investigational drug Apitegromab, ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Investing.com -- Scholar Rock Holding Corp (NASDAQ: SRRK) stock surged 16.4% after the company announced positive results from its Phase 2 EMBRAZE trial evaluating apitegromab in combination with ...